How Semax/Selank Buccal Delivery Is Compared With Intranasal Delivery in Peptide Research

How Semax/Selank buccal delivery is compared with intranasal delivery in peptide research is by keeping the two routes separate from the start, because most Semax and Selank work that exists is intranasal, while buccal work is largely film and model work, and a result from one route cannot be transferred to the other without a comparison designed to test that transfer, for either peptide, let alone for both together.

Most Semax and Selank work in people was done intranasally, not buccally. For an overview of the combined film, see Semax/Selank buccal strips research.

This article on how Semax/Selank buccal delivery is compared with intranasal delivery in peptide research is presented as research material only. It does not diagnose, treat, cure, or prevent any disease, does not recommend use in people, and does not present buccal strips as an approved drug or supplement for human consumption.

Why intranasal is the comparison that matters

Semax and Selank were both developed in Russia, and both were studied mainly intranasally, in Russian clinical and preclinical work. Intranasal delivery was proposed to reach the brain along olfactory pathways, bypassing first-pass digestive degradation, and it is the route for the Russian nasal products for both peptides, and for most of the human work reported for either peptide.

Buccal delivery is a different route. A film dissolves against the lining of the mouth, in a mucosal model, without the nasal epithelium, without olfactory pathways as a proposed route, and with saliva, dissolution, and swallowing as variables that an intranasal study does not have in the same form. A buccal film therefore cannot inherit an intranasal result simply because both forms contain the same peptides.

That is the central comparison problem for this product form, and it is why this article exists. Without a buccal versus intranasal comparison, a reader can easily take an intranasal Semax or Selank finding and present it as a buccal finding, when no buccal study ever measured that outcome, for either peptide, let alone for both together.

What each route measures, and what it does not

Intranasal studies measure what happens after nasal administration, in models and, in Russian work, in people: nasal deposition, olfactory pathway exposure as proposed, brain measures such as BDNF or monoamine changes for Semax, and GABAergic, enkephalin, or behavioural measures for Selank, depending on the study, with nasal irritation and other nasal tolerability measures where reported.

Buccal models measure different things: film dissolution, mucosal retention in a model, and permeation across a mucosal model in vitro. Those measures are about the film and the model barrier, not about brain BDNF, monoamine, GABAergic, or behavioural outcomes, and not about blood levels or systemic effect in people, unless a study is specifically designed to measure those outcomes, which buccal Semax/Selank studies, as a field, have not yet done in published human work.

Keeping those measure sets apart prevents the most common misreading in this topic: taking an intranasal brain or behavioural measure, and a buccal dissolution measure, and presenting them as if they were the same outcome, measured by the same route.

Barriers: nasal epithelium versus oral mucosa

Nasal epithelium and oral mucosa are not interchangeable barriers in research. Nasal delivery research is largely about deposition on the nasal epithelium, mucociliary clearance in the nose, and proposed olfactory and trigeminal pathways to the brain, all of which are specific to the nose. Oral mucosal research is largely about dissolution in saliva, retention against the lining of the mouth, permeation across oral mucosa in vitro, and swallowing loss, all of which are specific to the mouth.

A formulation that works for the nose may therefore fail for the mouth, and vice versa, for reasons that have nothing to do with Semax or Selank themselves. Vehicle, pH, moisture, contact time, and clearance all change with route, and a delivery comparison must account for those route variables, not just for the peptides.

That is also why general delivery format articles already on this site, which cover delivery format in general, are not a substitute for this article. They cover format in general. This article covers Semax and Selank, buccal versus intranasal, specifically, with both peptides’ intranasal records as the comparators.

How a fair buccal versus intranasal comparison would be designed

A fair comparison would start with the same peptides, in two defined vehicles, a buccal film and an intranasal form, tested in models appropriate to each route, with the same outcome measures where possible, and with route-specific measures reported separately where they cannot be matched.

It would report film dissolution and mucosal permeation for the buccal arm, and nasal deposition and brain measures for the intranasal arm, without forcing one arm’s measures onto the other. It would also report what was not measured in each arm, so a reader does not assume a missing measure was a negative result, or a positive result in one arm was a result in the other. For a combined film, it would do that for Semax and for Selank separately, not only as a combined total.

No published study, as far as the literature reviewed for this article shows, has yet done that full buccal versus intranasal comparison for Semax/Selank together in people, or for either peptide alone in a buccal film in people. That absence is itself a finding, and it is the main limit of this product form’s evidence base. It does not mean buccal delivery is worse, or better, than intranasal delivery. It means the comparison has not been made in people, and cannot be assumed.

What this comparison does not do

This article does not rank buccal and intranasal delivery for a person, does not recommend one route over the other, and does not present buccal delivery as a way to bypass the nose, or intranasal delivery as a way to bypass the mouth. It also does not use intranasal human data to support a buccal claim, or buccal model data to support an intranasal claim.

Film stability is a separate question, covered in how Semax/Selank buccal film stability is studied in peptide research. Stability tells a reader whether a film stayed the same film in storage. Delivery comparison tells a reader whether that film’s route can be compared with another route at all. Both are needed, and neither replaces the other.

External Evidence

Semax literature, as reviewed for this article, is centred on ACTH-fragment biology, BDNF and neurotrophic signalling in animal models, monoamine modulation, and Russian intranasal clinical work, largely open-label or poorly described in English-language reports, with limited independent Western replication, used here as the intranasal comparator for Semax, not as buccal evidence.

Selank literature, as reviewed for this article, is centred on tuftsin-derived biology, GABAergic modulation, enkephalin-degrading enzyme inhibition, and small Russian human intranasal anxiety work, with limited Western replication, used here as the intranasal comparator for Selank, not as buccal evidence.

What Buccal Versus Intranasal Comparison Research Can Establish

• How buccal and intranasal routes differ in barrier, vehicle, dissolution, deposition, and clearance, in defined models, for each peptide.
• What each route measures in its own models, and where those measures cannot be matched across routes.
• Whether a study design actually compares routes, or merely presents results from two different routes side by side.
• Where the evidence gap sits for Semax/Selank, namely, intranasal work without a matching buccal human comparison, for either peptide or for the combination.

What Buccal Versus Intranasal Comparison Research Does Not Establish

• That an intranasal Semax or Selank result is a buccal result, or that a buccal model result is an intranasal result, for either peptide or for the combination.
• That buccal delivery is better, worse, safer, or more effective than intranasal delivery in people, without a direct human comparison.
• That dissolution in a mucosal model equals absorption, blood levels, brain exposure, or effect in a person.
• That a single-peptide result in cells, animals, or intranasal studies bridges a route gap, or a combination gap, without route- and combination-specific data.

Final Perspective

For Semax and Selank, intranasal delivery is not just another route. It is the route with the human record, however small, Russian-language, and open-label much of that record is. Buccal delivery, by contrast, is the route with the film and model record, and without a matching human record. Any honest article must keep that asymmetry visible, rather than smoothing it over with a general claim about either peptide, or about the pair together.

Once that asymmetry is visible, the next question is narrower and more testable: how are the two signalling systems themselves compared, when both peptides are present together, and what measures would that comparison need?

For how Semax and Selank signalling systems are compared when both peptides are present together, see how Semax and Selank signaling are compared in combination research.

Related product: Semax/Selank Buccal Strips, Semax 500 mcg and Selank 500 mcg per film, 20 count, research material. Details on the product page.